StreetInsider.com News Articles

IVRO's Q3 Packed with Positives; Sales, Profits, and U.S. Government/Global Support for Animal Welfare

Tue, 05 Aug 2025 09:00:00 -0400

Placentia, California--(Newsfile Corp. - August 5, 2025) - Today, InVitro International (OTCQB: IVRO) reported FY '25, Q3 sales of $234,430, up 39.7% over the same period in FY '24. YTD sales of $675,080 are now 14.4% ahead of FY '24. Net income of $95,556 for three quarters in FY '25 is 17.1% ahead of the same three quarters in FY '24.

CEO and Chairman, W. Richard Ulmer, expressed delight with IVRO's noteworthy progress: "In recent months we received quite a few new inquiries. Many are from chemical companies who are realizing that animal testing is much more expensive, takes much

IVRO's Q3 Packed with Positives; Sales, Profits, and U.S. Government/Global Support for Animal Welfare

Tue, 05 Aug 2025 09:00:00 -0400

IVRO Continues Drive to Minimize Unnecessary Live Animal Testing

Tue, 13 May 2025 09:09:00 -0400

PLACENTIA, CA - May 13, 2025 (NEWMEDIAWIRE) - Today, InVitro International (OTCQB: IVRO) reported first half FY '25 sales of $440,650, up 4.4% vs. the same period in FY '24. Net income of $49,239 declined from $65,345 (24.7%) for the same six months in FY '24, reflecting inflationary and OTCQB increased costs.

CEO and Chairman, W. Richard Ulmer, enthused: "We believe IVRO's first half FY '25 indicates we may be entering a growth period for Non-Animal test technologies. Canada more recently passed legislation, now about to be joined by the U.S.A., follows Europe's 2013 ban on the introduction of new

IVRO Continues Drive to Minimize Unnecessary Live Animal Testing

Tue, 13 May 2025 09:09:00 -0400

IVRO Announces Strong FY '25 First Quarter Sales & Net Income Advances

Tue, 04 Feb 2025 09:00:00 -0400

Placentia, California--(Newsfile Corp. - February 4, 2025) - InVitro International (OTCQB: IVRO) today announced a solid 15.4% sales advance in Q1 of FY '25, totaling $244,143; this compares favorably to Q1 FY '24 sales of $211,625. FY '25 Q1 net income of $33,855 leapt 91.6% over the FY '24 Q1 figure of $17,667.

InVitro International's CEO and acting President, W. Richard Ulmer said: "Together with our newly announced M & A activity in Europe, our team is pleased with FY '25 first Quarter progress. Following Covid and inflationary years' challenges, InVitro International's vision of the future is continued global

IVRO Announces Strong FY '25 First Quarter Sales & Net Income Advances

Tue, 04 Feb 2025 09:00:00 -0400

Invitro International (IVRO) to Merge With a European Based Non-Animal Testing Focused Organization

Tue, 14 Jan 2025 09:02:40 -0400

InVitro International (OTCQB: IVRO) previously revealed its strategic intent to accelerate organic growth by pursuing mergers and acquisitions. Today we are excited to announce our initial action to implement this strategy. InVitro International's Board of Directors unanimously approved a Memorandum of Understanding (MOU) to merge with a European based non-animal testing focused organization which has served their market for more than two decades. Details regarding costs and timing of the agreed upon MOU will continue when the agreement is finalized.

CEO W. Richard Ulmer observed: "The global movement toward the humane goal of sparing animals from safety testing began in Europe

Invitro International (IVRO) to Merge With a European Based Non-Animal Testing Focused Organization

Tue, 14 Jan 2025 09:02:40 -0400

CEO W. Richard Ulmer observed: "The global movement toward the humane goal of sparing animals from safety testing began in Europe

IVRO Signs MOU to Merge With a European Based Non-Animal Testing Focused Organization

Tue, 14 Jan 2025 09:00:00 -0400

Placentia, California--(Newsfile Corp. - January 14, 2025) - InVitro International (OTCQB: IVRO) previously revealed its strategic intent to accelerate organic growth by pursuing mergers and acquisitions. Today we are excited to announce our initial action to implement this strategy. InVitro International's Board of Directors unanimously approved a Memorandum of Understanding (MOU) to merge with a European based non-animal testing focused organization which has served their market for more than two decades. Details regarding costs and timing of the agreed upon MOU will continue when the agreement is finalized.

CEO W. Richard Ulmer observed: "The global movement toward the humane goal of

IVRO Signs MOU to Merge With a European Based Non-Animal Testing Focused Organization

Tue, 14 Jan 2025 09:00:00 -0400

CEO W. Richard Ulmer observed: "The global movement toward the humane goal of

InVitro International: Expectations Remain High for Animal Welfare & Growth Opportunities

Wed, 04 Dec 2024 09:00:00 -0400

Placentia, California--(Newsfile Corp. - December 4, 2024) - Today InVitro International (OTCQB: IVRO) announced FY '24 sales of $811,290, up 2.4% vs. FY '23. Net income of $106,704 soared over the prior year's $1,555. Fourth quarter sales of $221,200 were 19.9% ahead of last year's same period while net income of $25,122 fell 48.8%, short of last year's 4^th quarter, $49,035.

While evaluating FY '24 financial results, CEO W. Richard Ulmer observed: "IVRO's Board of Directors is pleased with our 20^th consecutive year of profits. They believe we're positioned well to begin execution of our M & A growth strategy. Expectations

InVitro International: Expectations Remain High for Animal Welfare & Growth Opportunities

Wed, 04 Dec 2024 09:00:00 -0400

InVitro International Engages Askew Kabala and Company, Inc. to Further Advance Its Corporate Growth Plan

Tue, 03 Sep 2024 09:00:00 -0400

Placentia, California--(Newsfile Corp. - September 3, 2024) - Today InVitro International (OTCQB: IVRO) is pleased to announce that it has engaged Askew Kabala and Company, Inc. as consultant to the company. AKC will act in a business advising, investment banking, management and strategy role to support and advance IVRO's previously announced corporate growth plan. AKC will provide executive and organizational support, including strategy refinement, planning and operational review & more where needed & appropriate.

IVRO CEO, W. Richard Ulmer, said: "InVitro believes it is adapting well to post-Covid '19 & inflationary times by adding guidance from experienced minds with

InVitro International Engages Askew Kabala and Company, Inc. to Further Advance Its Corporate Growth Plan

Tue, 03 Sep 2024 09:00:00 -0400

IVRO CEO, W. Richard Ulmer, said: "InVitro believes it is adapting well to post-Covid '19 & inflationary times by adding guidance from experienced minds with

InVitro International Progresses with Growth Strategies and Continues Profitability

Wed, 31 Jul 2024 09:00:00 -0400

Placentia, California--(Newsfile Corp. - July 31, 2024) - Today, InVitro International (OTCQB: IVRO) announced third quarter FY '24 sales of $167,850, off 16% vs the same quarter last year. Net income of $16,236 compared favorably with losses of $13,162 in the same quarter FY'23. Three quarters FY'24 sales of $590,090 were 3% off FY'23's total of $608,195; however, year to date earnings of $81,582 are 272% ahead of prior year losses of $47,480.

IVRO CEO W. Richard Ulmer stated: "Our FY '24 focus has been on continuing 19 consecutive years of profitability, in addition to concentrating efforts on growth via

InVitro International Progresses with Growth Strategies and Continues Profitability

Wed, 31 Jul 2024 09:00:00 -0400

IVRO CEO W. Richard Ulmer stated: "Our FY '24 focus has been on continuing 19 consecutive years of profitability, in addition to concentrating efforts on growth via